Evidence map›Paper›PMID 24773414›Full record

ArticleNeuropsychology2014

Eye movements reveal impaired inhibitory control in adult male fragile X premutation carriers asymptomatic for FXTAS.

Ling M Wong, Naomi J Goodrich-Hunsaker, Yingratana McLennan, Flora Tassone, Melody Zhang, Susan M Rivera, Tony J Simon

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Neuropsychology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Sensorimotor and inhibitory control in agingFrontiers in human neuroscience · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ling M WongDepartment of Psychiatry and Behavioral Sciences, University of California, Davis Medical Center.ORCID 0000-0002-6045-5344
Naomi J Goodrich-HunsakerDepartment of Psychiatry and Behavioral Sciences, University of California, Davis Medical Center.
Yingratana McLennanDepartment of Psychiatry and Behavioral Sciences, University of California, Davis Medical Center.
Flora TassoneDepartment of Biochemistry and Molecular Medicine, University of California, Davis Medical Center.
Melody ZhangDepartment of Neurobiology, Physiology, and Behavior, University of California, Davis.
Susan M RiveraDepartment of Psychology, University of California, Davis.
Tony J SimonDepartment of Psychiatry and Behavioral Sciences, University of California, Davis Medical Center.
University of California Davis Medical Center · USUniversity of California, Davis · US

Funding

Trajectories and Markers of Neurodegeneration in Fragile X Premutation CarriersR01MH078041 · NIMH · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HESSL, DAVID R, RIVERA, SUSAN M · 2007 to 2017
$5.4M
Development of targeted therapeutic agents for the treatment of FXTAS (2 of 6)RL1AG032119 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, PAUL J · 2007 to 2011
$4.1M
Neuro Therapeutics Research Institute (1 of 6)UL1DE019583 · NIDCR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, PAUL J · 2008 to 2011
$3.0M
Fragile X Spectrum as Model for Neurogenetic Mechanisms of Cognitive DysfunctionRL1NS062412 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SIMON, TONY J · 2007 to 2011
$2.7M
Interdisciplinary Training Program in Neurotherapeutics (6 of 6)TL1DA024854 · NIDA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARTER, CAMERON S. · 2007 to 2011
$835k
NIA NIH HHS RL1 AG032119NIDA NIH HHS TL1 DA024854NIDCR NIH HHS UL1 DE019583NIMH NIH HHS MH078041NINDS NIH HHS RL1 NS062412NINDS NIH HHS RL1 NS062412-S1
6 · The paper itself

Abstract

objectiveFragile X premutation carriers (fXPCs) have an expansion of 55-200 CGG repeats in the FMR1 gene. Male fXPCs are at risk for developing a neurodegenerative motor disorder (FXTAS) often accompanied by inhibitory control impairments, even in fXPCs without motor symptoms. Inhibitory control impairments might precede, and thus indicate elevated risk for motor impairment associated with FXTAS. We tested whether inhibitory impairments are observable in fXPCs by assessing oculomotor performance.

methodParticipants were males aged 18-48 years asymptomatic for FXTAS. FXPCs (n = 21) and healthy age-matched controls (n = 22) performed four oculomotor tasks. In a Fixation task, participants fixated on a central cross and maintained gaze position when a peripheral stimulus appeared. In a Pursuit task, participants maintained gaze on a square moving at constant velocity. In a Prosaccade task, participants fixated on a central cross, then looked at a peripheral stimulus. An Antisaccade task was identical to the Prosaccade task, except participants looked in the direction opposite the stimulus. Inhibitory cost was the difference in saccade latency between the Antisaccade and Prosaccade tasks.

resultsRelative to controls, fXPCs had longer saccade latency in the Antisaccade task. In fXPCs, inhibitory cost was positively associated with vermis area in lobules VI-VII.

conclusionAntisaccades require inhibitory control to inhibit reflexive eye movements. We found that eye movements are sensitive to impaired inhibitory control in fXPCs asymptomatic for FXTAS. Thus, eye movements may be useful in assessing FXTAS risk or disease progression.

Indexed as

Inhibition, PsychologicalAdolescentAdultAttention Deficit Disorder with HyperactivityCerebellar CortexCognition DisordersExecutive FunctionFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeHumansLinear ModelsMagnetic Resonance ImagingMaleMiddle AgedOcular Motility DisordersPrimary Ovarian InsufficiencyFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1

Identifiers

PMID24773414
PMCPMC4172343
OpenAlexW2122375034

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.